Low-dose bevacizumab with standard radiation for DIPG
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 2 study tests whether adding low-dose bevacizumab (a medicine that affects blood vessel growth) to standard radiation can help children newly diagnosed with DIPG. It’s meant for certain children with a specific type of brain tumor that has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 3 to 18 years old at diagnosis
- DIPG is newly diagnosed and hasn’t spread elsewhere (“non-disseminated”), based on symptoms and scans
- At screening, they can do daily activities at a moderate level (KPS/LPS score is at least 50)
- Recent blood and urine tests are in safe ranges (neutrophils, platelets, hemoglobin; liver and kidney; and urine protein is not too high)
- Blood clot history is negative (no prior deep vein/arterial clot or pulmonary embolism, and no known clotting condition)
- They should not have a serious allergy to similar biologic antibody medicines, and they should be safe for MRI without special issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat a type of brain tumor called diffuse midline glioma. It uses focused ultrasound to open a tiny gap in the blood-brain barrier, which may help special immune cells (T-cells) reach and attack the tumor. The goal is to see if this combination is safe and helpful.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial compares two types of radiation therapy for children with diffuse intrinsic pontine glioma (DIPG), a rare brain tumor. It aims to see which treatment may be more effective while helping you understand your options.
This Phase 1 trial tests a type of cancer-fighting virus given directly into the tumor for children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The goal is to see if it can be delivered safely and to learn how the body responds to it.
This trial tests whether adding sonodynamic therapy (a treatment that uses sound waves to activate a drug) before standard radiation and chemotherapy can help people with a type of brainstem glioma called DIPG. The goal is to see if this combination improves survival.
Hear when a new DIPG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.